Our pipeline

Portfolio Overview

Our non-surgical, proprietary delivery platform requires no capital equipment and leverages existing intrauterine techniques. Our minimally invasive technologies are designed to provide safe, convenient in-office approaches, saving time and reducing costs.

Femasys has an expansive, internally-created intellectual property portfolio with over 130 patents issued globally for our products and product candidates.

Infertility Products and Product Candidates

Research
Preclinical
De Novo Clinical Study

FemaSeed®

Localized Directional
Insemination

Research
Preclinical
De Novo Clinical Study
Anticipated Milestones
  • IDE approval received from FDA in April 2021
  • Commenced De Novo clinical trial third quarter of 2021 with planned completion in 2022
Research
Preclinical
Approval

Infertility Products and Product Candidates

FemVue®

Contrast-Generating Device

Research
Preclinical
Approval
Commercially Available
Anticipated Milestones
  • Expand commercialization

FemCath™

Selective Delivery Catheter

Coming Soon
Anticipated Milestones
  • Commercialize in 2022

Contraception Product Candidate

Research
Preclinical
PMA Clinical Studies
STAGE I
STAGE II
STAGE III

Contraception Product Candidate

Permanent Birth Control and Ultrasound Occlusion Confirmation

Research
Preclinical
PMA Clinical Studies
Anticipated Milestones
  • Commence PMA clinical trial after combined IDE submission approval in 2022

Biopsy Product

Research
Preclinical
Approval

Biopsy Product

Endocervical Tissue Sampler

Research
Preclinical
Approval
Coming Soon
Anticipated Milestones
  • Commercialize in 2022

FemEMB™

Endometrial Biopsy

CE = European Commission
IDE = Investigational Device Exemption
FDA = Food and Drug Administration
PMA = Premarket approval

Infertility

FemaSeed®

FemaSeed is a novel solution in development for insemination that can be performed as a first-line therapeutic option. It would be the first and only directed approach designed to be more affordable than assisted reproduction, such as in vitro fertilization (IVF).

Femvue® | FemCath™

FemVue is the first FDA-cleared product that delivers natural saline and air as contrast for diagnosis of the fallopian tubes with ultrasound. When paired with FemCath, an FDA-cleared intrauterine catheter, each tube can be selected for individual evaluation. This safe and reliable procedure provides real-time results and can be done along with a uterine cavity assessment for a comprehensive infertility diagnosis.
Husband comforting wife as they meet with doctor about infertility
Family of three embracing

FemBloc®

FemBloc is in development as the first and only in-office approach to permanent birth control without the need for anesthesia or special equipment, which would make this nonsurgical option easy to incorporate into existing practices worldwide. With a potential to be less than half the total cost of a surgical tubal ligation, FemBloc enriches the physician’s practice. FemBloc also features the first and only ultrasound approach to confirm success 90 days after the procedure.

Other Products

FemCerv®

FemCerv is the first and only approach for comprehensive tissue sampling for the diagnosis of cervical cancer. We intend to market this diagnostic option alongside our other female-specific medical products to physicians’ offices.